Literature DB >> 11176456

Distinct microsatellite alterations in upper urinary tract tumors and subsequent bladder tumors.

T Takahashi1, Y Kakehi, K Mitsumori, T Akao, T Terachi, T Kato, O Ogawa, T Habuchi.   

Abstract

PURPOSE: Although synchronous and/or metachronous tumor development is common in urothelial cancer, genetic and biological differences in upper urinary tract and bladder tumors are unclear. We compared the genetic alteration pattern in multifocal disease in patients with upper urinary tract and subsequent bladder tumors, and those with recurrent bladder tumor.
MATERIALS AND METHODS: Using 21 microsatellite markers on the 8 chromosomal arms 2q, 4p, 4q, 8p, 9p, 9q, 11p and 17p we analyzed 34 tumors from 15 patients with upper urinary tract and subsequent bladder disease, and 70 tumors from 22 with recurrent bladder disease.
RESULTS: Judging from the patterns of genetic alterations multifocal tumors were considered to have derived from an identical progenitor cell in 7 of 13 evaluable patients (54%) with upper urinary tract and subsequent bladder tumors, and 16 of 19 (84%) who were evaluable with recurrent bladder tumor. These data confirm the view that seeding or intraepithelial spread is a major mechanism for the multifocal development of urothelial cancer in general. However, a discordant microsatellite alteration pattern in multifocal tumors was observed in 6 of 7 patients (86%) with upper urinary tract and subsequent bladder lesions but in 2 of 16 (13%) with recurrent bladder cancer (p <0.005).
CONCLUSIONS: Our results imply that upper urinary tract neoplasms may be genetically more unstable than bladder neoplasms. The implantation of tumor cells from upper urinary tract to bladder may involve additional and diverse genetic alterations. Furthermore, a considerable number of multifocal upper urinary tract and subsequent bladder lesions may arise independently via field cancerization mechanism. Our study indicates that the factors contributing to multifocal development are different in the 2 groups.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11176456     DOI: 10.1097/00005392-200102000-00092

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  15 in total

1.  [Diagnostic procedures in upper urinary tract urothelial carcinoma].

Authors:  O Patschan; M Horstmann; C Thomas; H P Schlemmer; A Stenzl
Journal:  Urologe A       Date:  2008-11       Impact factor: 0.639

2.  UroVysion® predicts intravesical recurrence after radical nephroureterectomy for urothelial carcinoma of the upper urinary tract: a prospective study.

Authors:  Hidehiro Iwata; Naoto Sassa; Masashi Kato; Yota Murase; Shuko Seko; Hideji Kawanishi; Ryohei Hattori; Momokazu Gotoh; Toyonori Tsuzuki
Journal:  Int J Clin Oncol       Date:  2020-09-21       Impact factor: 3.402

Review 3.  Tissue engineering for the oncologic urinary bladder.

Authors:  Tomasz Drewa; Jan Adamowicz; Arun Sharma
Journal:  Nat Rev Urol       Date:  2012-08-21       Impact factor: 14.432

4.  Increased Rac1 activity and Pak1 overexpression are associated with lymphovascular invasion and lymph node metastasis of upper urinary tract cancer.

Authors:  Takao Kamai; Hiromichi Shirataki; Kimihiro Nakanishi; Nobutaka Furuya; Tsunehito Kambara; Hideyuki Abe; Tetsunari Oyama; Ken-Ichiro Yoshida
Journal:  BMC Cancer       Date:  2010-04-28       Impact factor: 4.430

5.  Shared occupational risks for transitional cell cancer of the bladder and renal pelvis among men and women in Sweden.

Authors:  Robin Taylor Wilson; Mark Donahue; Gloria Gridley; Johanna Adami; Laure El Ghormli; Mustafa Dosemeci
Journal:  Am J Ind Med       Date:  2008-02       Impact factor: 2.214

6.  Dynamic Change in p63 Protein Expression during Implantation of Urothelial Cancer Clusters.

Authors:  Takahiro Yoshida; Hiroaki Okuyama; Masashi Nakayama; Hiroko Endo; Yasuhiko Tomita; Norio Nonomura; Kazuo Nishimura; Masahiro Inoue
Journal:  Neoplasia       Date:  2015-07       Impact factor: 5.715

7.  Comparison of the clonality of urothelial carcinoma developing in the upper urinary tract and those developing in the bladder.

Authors:  Yuding Wang; Michael R Lang; Christopher L Pin; Jonathan I Izawa
Journal:  Springerplus       Date:  2013-08-28

8.  Ureteral involvement and diabetes increase the risk of subsequent bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma.

Authors:  Che-Yuan Hu; Yu-Chieh Tsai; Shuo-Meng Wang; Chao-Yuan Huang; Huai-Ching Tai; Chung-Hsin Chen; Yeong-Shiau Pu; Wei-Chou Lin; Kuo-How Huang
Journal:  Biomed Res Int       Date:  2015-03-31       Impact factor: 3.411

9.  Holmium laser transurethral resection of bladder tumor: Our experience.

Authors:  Nischith D'souza; Ashish Verma
Journal:  Urol Ann       Date:  2016 Oct-Dec

10.  High frequency of bladder cancer after nephroureterectomy: justification for adjuvant intravesical treatment?

Authors:  Matan Mekayten; Vladimir Yutkin; Mordechai Duvdevani; Dov Pode; Guy Hidas; Ezekiel H Landau; Fadi Youssef; Ofer N Gofrit
Journal:  Res Rep Urol       Date:  2018-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.